Skyhawk Therapeutics annonce l'extension aux États-Unis, au Canada et au Royaume-Uni de son essai clinique pivot mondial FALCON-HD portant sur le médicament SKY-0515 dans le traitement de la maladie de Huntington

Summary

Skyhawk Therapeutics announced expansion of its FALCON-HD pivotal trial for SKY-0515 in Huntington's disease to the United States, Canada, and United Kingdom, with over 175 patients recruited across more than 10 countries and 20 sites. The Phase 1/2 study recruitment has been completed.